Archimedes Development Ltd, leading an international consortium of eight members has received EC funding totalling 3.57 million, over three years, for a collaborative, small/medium-scale focused research project to reduce the threat of an avian influenza pandemic by developing a nasal vaccine.








The Nasal Pandemic Influenza Vaccine (NASPANVAC) project is funded by the European Commission under the FP7 scheme.